PEDIA-LAX ENEMA OTC
Generic Name and Formulations:
Monobasic sodium phosphate 9.5g, dibasic sodium phosphate 3.5g; per 59mL; latex-free; contains 2.2g sodium per enema.
Fleet, C.B., Company
Indications for PEDIA-LAX ENEMA:
Occasional constipation or bowel cleansing before rectal exam.
<2yrs: do not use. 2–4yrs: ½ enema rectally. 5–11yrs: 1 enema rectally. Results usually in 1–5 min; reevaluate if ineffective.
CHF. Ascites. Severe renal impairment. GI or GU obstruction. Megacolon. Imperforate anus.
Sodium-restricted diet. Impaired renal or cardiac function. Electrolyte disturbances. Colostomy. Discontinue if rectal bleeding or if no bowel movement occurs. Frequent use leads to dependence.
Electrolyte imbalances possible with calcium channel blockers, diuretics; use cautiously.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|